Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2009095395) PHARMACEUTICAL COMPOSITIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2009/095395 International Application No.: PCT/EP2009/050924
Publication Date: 06.08.2009 International Filing Date: 28.01.2009
IPC:
A61K 9/32 (2006.01) ,A61K 9/36 (2006.01) ,A61K 31/137 (2006.01) ,A61K 31/343 (2006.01) ,A61K 31/554 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
30
Organic coatings
32
containing solid synthetic polymers
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
30
Organic coatings
36
containing carbohydrates or derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
137
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
554
having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
Applicants:
BIOVAIL LABORATORIES INTERNATIONAL SRL [BB/BB]; Welches Barbados West Indies Christ Church 17154, BB (AllExceptUS)
WALSH, Edwin [IE/IE]; IE (UsOnly)
JACKSON, Graham [GB/BB]; BB (UsOnly)
OBEREGGER, Werner [CA/CA]; CA (UsOnly)
XIAOPIN, Jin [CA/CA]; CA (UsOnly)
Inventors:
WALSH, Edwin; IE
JACKSON, Graham; BB
OBEREGGER, Werner; CA
XIAOPIN, Jin; CA
Agent:
DUNNE, Sinead; TOMKINS & CO. 5 Dartmouth Road Dublin 6, IE
Priority Data:
61/023,95128.01.2008US
Title (EN) PHARMACEUTICAL COMPOSITIONS
(FR) COMPOSITIONS PHARMACEUTIQUES
Abstract:
(EN) The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.
(FR) La présente invention porte sur une composition pharmaceutique comprenant un cœur de comprimé comprenant une combinaison d'actifs choisis dans le groupe constitué par le chlorhydrate de bupropion et l'oxalate d'escitalopram, le bromhydrate de bupropion et le chlorhydrate de citalopram, le bromhydrate de bupropion et l'oxalate d'escitalopram, et le bromhydrate de bupropion et le fumarate de quétiapine, et au moins un excipient pharmaceutiquement acceptable, et un enrobage de libération contrôlée entourant le cœur de comprimé, ladite composition assurant de façon surprenante une libération synchrone de la combinaison d'agents actif in-vitro. La composition pharmaceutique à dose quotidienne unique assure également de façon surprenante une absorption accrue du bromhydrate de bupropion lorsqu'elle est administrée à un sujet nécessitant une telle administration.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)